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Abstract
Background: High cost, poor compliance, and systemic toxicity have limited the use of pentavalent antimony compounds
(SbV), the treatment of choice for cutaneous leishmaniasis (CL). Paromomycin (PR) has been developed as an alternative to
SbV, but existing data are conflicting.
Methodology/Principal Findings: We searched PubMed, Scopus, and Cochrane Central Register of Controlled Trials,
without language restriction, through August 2007, to identify randomized controlled trials that compared the efficacy or
safety between PR and placebo or SbV. Primary outcome was clinical cure, defined as complete healing, disappearance, or
reepithelialization of all lesions. Data were extracted independently by two investigators, and pooled using a random-
effects model. Fourteen trials including 1,221 patients were included. In placebo-controlled trials, topical PR appeared to
have therapeutic activity against the old world and new world CL, with increased local reactions, when used with
methylbenzethonium chloride (MBCL) compared to when used alone (risk ratio [RR] for clinical cure, 2.58 versus 1.01: RR for
local reactions, 1.60 versus 1.07). In SbV-controlled trials, the efficacy of topical PR was not significantly different from that of
intralesional SbV in the old world CL (RR, 0.70; 95% confidence interval, 0.26–1.89), whereas topical PR was inferior to
parenteral SbV in treating the new world CL (0.67; 0.54–0.82). No significant difference in efficacy was found between
parenteral PR and parenteral SbV in the new world CL (0.88; 0.56–1.38). Systemic side effects were fewer with topical or
parenteral PR than parenteral SbV.
Conclusions/Significance: Topical PR with MBCL could be a therapeutic alternative to SbV in selected cases of the old world
CL. Development of new formulations with better efficacy and tolerability remains to be an area of future research.
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Introduction
More than 12 million people in 88 countries suffer from
leishmaniasis, a condition caused by parasites of the genus
Leishmania [1]. Annually, two million new cases of leishmaniasis
are diagnosed, of which about one quarter present as visceral
leishmaniasis, a potentially fatal condition. The rest present as
cutaneous leishmaniasis (CL), a non-fatal yet severely disfiguring
condition characterized by skin lesions and unsightly scars on the
face and extremities. Over the past decade, the worldwide
prevalence and geographical distribution of CL have expanded.
Pentavalent antimony compounds (SbV), such as sodium
stibogluconate (SB) or meglumine antimoniate (MA), have been
the mainstay of the treatments [2]. Despite its efficacy, SbV is
limited by high cost, poor compliance due to a prolonged course of
intramuscular or intravenous injections, and potentially reversible
systemic toxicity [3–6]. Resistance is also of particular concern [7].
Among various species causing the old world and new world CL,
certain species are more likely to self-cure at a slower rate or
progress to diffuse or mucocutaneous form than others [8]. Due to
such clinical significance, the treatment has been mainly in the
form of topical application in the old world CL and systemic in the
new world CL. Seeking an alternative to SbV for localized CL has
been of particular interest over the past decades.
Therapeutic activity of paromomycin (synonymous with
aminosidine) (PR) was first reported in the 1960’s [9,10]. In the
1980’s, El-On et al. demonstrated therapeutic activity of PR in an
in vitro study [11]. Epicutaneous administration of PR (topical PR,
hereafter) with 12% MBCL (‘‘first-generation formulation’’)
further showed promising results in animal [12] and human
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studies [13]. In the early 1990’s, MBCL was replaced with urea to
reduce local side effects from MBCL (‘‘second-generation
formulation’’) [14,15]. Even though PR has also been adminis-
tered parenterally [4,5], topical PR, in particular, has several
advantages over SbV, because of its fewer systemic side effects,
lower cost, and convenience [3,16,17]. Thus, it could be a good
therapeutic alternative to SbV. However, clinical trials of topical
PR and parenteral PR have showed widely varying results on the
efficacy and safety in treating CL. Its cure rate ranges from 4%
[18] to 93% [4] and its efficacy compared with SbV has been
equivocal [19]. Therefore, we performed a systematic review and
meta-analysis to assess the efficacy and safety of various PR
regimens as compared to placebo and SbV.
Methods
Data sources and study selection
We searched PubMed, Scopus, and Cochrane Central Register of
Controlled Trials, with no language restriction, from inception
through August 2007, to identify all randomized controlled trials
evaluating the efficacy and safety of PR for CL, using the following
search terms: cutaneous leishmaniasis, paromomycin, aminosidine, and
randomized controlled trials. Detailed strategies are described in
Appendix S1. The initial search was complemented by a manual
search of the reference lists from the retrieved articles and the
‘‘Related Articles’’ function of PubMed. Because various types of PR
and SbV regimens were tested, we tried to make clinically meaningful
comparisons by pooling the data within similar groups of trials.
Reports were excluded according to the following a priori criteria:
1) reviews, meta-analyses, or editorials; 2) case reports or
retrospective studies; 3) animal or in-vitro studies; 4) no randomized
control group; and 5) no data on efficacy or safety outcomes of PR
treatment. When a study originated several reports [5,20], the
report with the largest sample size or the longest follow-up was
included [5]. We further excluded two trials that compared different
duration or dose of PR without placebo or SbV control group
[21,22]; one trial that compared different MA regimens as an
augmentation of the same topical PR regimen [23]; two trials that
randomized lesions instead of patients [18,24] (because certain local
treatments may lead to improvement in untreated lesions in the
same individual [25,26]); and four trials that compared PR with
second-line treatments such as pentamidine [4], ketoconazole [27],
and photodynamic therapy [24,28]. All the retrieved reports were
independently reviewed by two investigators (HJC and DHK) for
eligibility and any disagreements were resolved by consensus.
Data extraction and validity assessment
Two investigators (HJC and DHK) independently extracted
data on participants’ characteristics, predominant parasite species,
interventions, and outcomes from included reports by using a
standardized data collection form. When the parasite species were
not reported, we assumed that it was the same as in other trials
conducted in the same geographical region [17,27,29]. We
evaluated the quality of studies using the following criteria: 1)
double-blind; 2) concealment of treatment allocation; 3) blinding
of outcome assessment; and 4) intention-to-treat analysis. Con-
cealment of treatment allocation was adequate if patients and
enrolling investigators could not predict assignment. Outcome
assessment was blinded if the investigator who assessed the
outcome had no knowledge of treatment assignment. The analysis
was performed according to the intention-to-treat principle if all
randomized patients were included in the analysis and kept in the
originally assigned groups. If there was not enough information to
assess the quality, it was assumed inadequate. Any disagreements
were resolved by consensus.
The main outcome was clinical cure, defined as complete
healing, disappearance, or reepithelialization of all lesions. The
secondary outcome was clinical improvement, defined as complete
or incomplete healing or reepithelialization of the lesion or any
reduction in the size. In addition, local and systemic side effects
were assessed. Local side effects included pain, burning sensation,
pruritus, erythema, edema, and inflammation at the administra-
tion site. Systemic side effects included myalgia, generalized
symptoms (i.e. fever, malaise, weakness, and anorexia), headache,
arthralgia, generalized eruptions, and laboratory abnormalities on
blood counts, chemistry, and liver function tests.
Quantitative data synthesis
Trials with placebo control group were analyzed separately
from trials with SbV control group. Pooled estimates and 95%
confidence intervals (CIs) of risk ratios (RRs) were calculated by
using an inverse-variance weighted random-effects model [30]
according to the intention-to-treat principle. Between-study
heterogeneity was quantified using the x2 and I2 statistics [31].
A random-effects meta-regression analysis was performed to
evaluate whether the heterogeneity among trials with placebo
control group was explained by duration of lesion, length of PR
treatment, and type of PR regimen. Duration of lesion and length
of PR treatment have been proposed as potential explanations for
inconsistent results in previous studies [27,32]. Although different
species or type of SbV regimen could have contributed to the
heterogeneity, we were not able to examine such factors due to an
insufficient number of trials. In addition, the influence of the study
quality criteria was evaluated. We chose this approach rather than
excluding trials based on a composite quality scale, because
disagreement between different scales is common and valuable
information may get excluded by the latter approach. We
conducted sensitivity analysis by examining the relative influence
Author Summary
Millions of people worldwide are suffering from cutaneous
leishmaniasis that is caused by parasites of the genus
Leishmania. Although pentavalent antimony compounds
are the treatment of choice, their use is limited by high
cost, poor compliance, and systemic toxicity. Paromomycin
was developed to overcome such limitations. However,
there is no consensus on its efficacy. This meta-analysis
assessed the efficacy and safety of paromomycin com-
pared with placebo and pentavalent antimony com-
pounds. Fourteen randomized controlled trials, including
1,221 patients, met our selection criteria. Topical paromo-
mycin appeared to have therapeutic activity against the
old world and new world cutaneous leishmaniasis, with
increased local reactions, when combined with methyl-
benzethonium chloride. Topical paromomycin was not
significantly different from intralesional pentavalent anti-
mony compounds in treating the old world form, whereas
it was inferior to parenteral pentavalent antimony
compounds in treating the new world form. However, a
similar efficacy was found between parenteral paromomy-
cin and pentavalent antimony compounds in treating the
new world form. Fewer systemic side effects were
observed with topical and parenteral paromomycin than
pentavalent antimony compounds. These results suggest
that topical paromomycin with methylbenzethonium
chloride could be a therapeutic alternative to pentavalent
antimony compounds for selected cases of the old world
cutaneous leishmaniasis.
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of each study on the pooled estimate by excluding one study at a
time. Finally, a publication bias was examined by the Begg’s test
(rank correlation method) and Egger’s test (weighted regression).
Statistical significance was defined as P,0.05 and all statistical
analyses were conducted with Stata/SE version 9.2 (StataCorp,
College Station, TX).
Results
Trial flow and study characteristics
Fourteen randomized controlled trials with a total of 1,221
patients satisfied our selection criteria [3–6,16,17,28,29,32–37].
The study selection process was summarized in Figure 1.
Table 1 summarizes the study characteristics. Eight trials
[17,28,29,32–34,36,37] were conducted in the Middle East and
North Africa where CL was caused by L.major (old world CL), and
six trials [3–6,16,35] were conducted in Central and South
America where CL was caused by L.braziliensis, L.panamensis, and
L.chagasi (new world CL). The mean age ranged from 5 to 24 years
and the proportion of male varied between 42% and 100%. The
average duration of lesions ranged from 15 to 105 days. Four types
of PR regimen were evaluated: topical PR alone [17,29,32–36];
topical PR with MBCL [3,6,16,28,37]; topical PR with MBCL
and parenteral MA [6]; and parenteral PR [4,5]. Ointment was
used for all topical formulations, except for one trial [29] where a
lotion form was used. Three trials [16,28,37] used MBCL as a
Figure 1. Flow Diagram of the Study Selection Process. Abbreviations: CENTRAL, Cochrane Central Register of Controlled Trials; RCT,
randomized controlled trials. * When a trial involved a second-line treatment as well as placebo or pentavalent antimony compounds, the data on
placebo [28] or pentavalent antimony compounds [4] were included.
doi:10.1371/journal.pntd.0000381.g001
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vehicle, whereas four [29,32,34,35] used urea and one [36] used a
paraffin and wool fat vehicle. Among SbV-controlled trials, two
trials [17,33] used intralesional regimen and four [3–6] used
parenteral regimen. After a follow-up period of 27 to 455 days, the
efficacy was assessed clinically [3,6,16,17,35] or in combination
with parasitological examination [4,5,28,29,32–34,36,37]. Seven
[16,28,29,32,34,35,37] were double-blinded and two [3,6] were
only double-blinded with respect to topical treatment.
Efficacy of PR versus placebo
Absolute rate of clinical cure comparing PR regimen versus
placebo varied: 13% to 74% versus 10% to 68% for L. major; 4%
versus 3% for L.chagasi; and 82% versus 34% for L.braziliensis.
Overall, any PR regimen was more effective than placebo to
achieve clinical cure (RR: 1.49; 95% CI: 1.04–2.13; P = 0.031;
heterogeneity x2=22.33, P= 0.002, I2=69%). (Figure 2) The RRs
(95% CIs) from six trials of the old world CL and from two trials of
the new world CL were 1.27 (0.91–1.77; P= 0.165; heterogeneity
x2=11.93, P= 0.036, I2=58%) and 2.34 (1.48–3.71; P,0.001;
heterogeneity x2=0.18, P= 0.668, I2=0%), respectively. The
meta-regression analysis suggested the type of PR regimen as a
main source of heterogeneity (P = 0.024), but neither the duration
of lesion nor the length of treatment. The heterogeneity
disappeared (I2=0%), when the data were pooled according to
the type of PR regimen. Topical PR was more effective than
placebo when it was combined with MBCL (2.58; 1.76–3.76;
P,0.001; heterogeneity x2=0.37, P= 0.830, I2=0%) compared
to when it was used alone (1.01; 0.87–1.18; P = 0.867; heteroge-
neity x2=1.82, P = 0.769, I2=0%). The results for the secondary
outcome were similar (data not shown).
Efficacy of PR versus SbV
Table 2 summarizes the existing data on efficacy of PR regimen
as compared to controls. In the old world CL, the evidence only
addressed the comparison between topical PR and intralesional
MA. No trials compared topical PR or parenteral PR with
parenteral SbV. In the new world CL, various topical or
parenteral PR regimens were compared with parenteral SbV,
but no trials compared any PR regimens with intralesional SbV.
Data from SbV-controlled trials were pooled by the type of PR
and SbV regimens. Absolute rate of clinical cure comparing
various PR regimens versus SbV regimens was the following: 17%
to 67% versus 42% to 60% for L.major; 59% to 93% versus 88%
for L.braziliensis; and 45% to 48% versus 69% to 70% for L.
panamensis. Overall, any PR regimen was less effective than any
SbV regimen to achieve clinical cure (0.77; 0.59–0.99; P = 0.043;
heterogeneity x2=16.08, P= 0.007, I2=69%). (Figure 3) In the
old world CL, the efficacy of topical PR was not significantly
Figure 2. Meta-analysis of the Efficacy of Paromomycin Compared with Placebo*. Abbreviations: CI, confidence interval; CL, cutaneous
leishmaniasis; MBCL, methylbenzethonium chloride; PR, paromomycin; RR, risk ratio. * Pooled RRs and 95% CIs of clinical cure were calculated using
an inverse-variance weighted random-effects model and displayed in diamonds in the figure. The I2 statistic describes the percentage of total
variation across the studies that is attributable to heterogeneity rather than chance.
doi:10.1371/journal.pntd.0000381.g002
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Table 2. Summary of Trials Comparing Paromomycin with Placebo or Antimony Compounds*.
Type of CL Paromomycin Regimen Control Group
Placebo Intralesional SbV Parenteral SbV
Old World CL Topical PR only 1.01 (0.87, 1.18)[29,32,34,36] 0.70 (0.26, 1.89)[17,33] No data
Topical PR/MBCL 2.99 (1.56, 5.75)[28,37] No data No data
Parenteral PR No data No data No data
New World CL Topical PR only 1.30 (0.09, 19.8)[35] No data 0.68 (0.46, 1.00)[3]
Topical PR/MBCL 2.39 (1.50, 3.80)[16] No data 0.68 (0.46, 1.00)[3]
Topical PR/MBCL/Parenteral SbV No data No data 0.65 (0.49, 0.87)[6]
Parenteral PR No data No data 0.88 (0.56, 1.38)[4,5]
Abbreviations: CL, cutaneous leishmaniasis; SbV, pentavalent antimony compounds (including meglumine antimoniate and sodium stibogluconate); PR, paromomycin;
MBCL, methylbenzethonium chloride.
*Pooled RRs and 95% CIs of clinical cure were calculated using an inverse-variance weighted random-effects model. Pooled RRs greater than 1 indicate that the results
favor paromomycin regimen to control regimen.
doi:10.1371/journal.pntd.0000381.t002
Figure 3. Meta-analysis of the Efficacy of Paromomycin Compared with Pentavalent Antimony Compounds*{. Abbreviations: CI,
confidence interval; CL, cutaneous leishmaniasis; MA, meglumine antimoniate; MBCL, methylbenzethonium chloride; PR, paromomycin; RR, risk ratio;
SB, sodium stibogluconate. * Pooled RRs and 95% CIs of clinical cure were calculated using an inverse-variance weighted random-effects model and
displayed in diamonds in the figure. The I2 statistic describes the percentage of total variation across the studies that is attributable to heterogeneity
rather than chance. { Parenteral antimony compounds include parenteral MA and parenteral SB.
doi:10.1371/journal.pntd.0000381.g003
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different from that of intralesional MA (0.70; 0.26–1.89; P = 0.480;
heterogeneity x2=6.06, P= 0.014, I2=84%). In the new world
CL, topical PR was less effective than parenteral MA (0.67; 0.54–
0.82; P,0.001; heterogeneity x2=0.03, P= 0.856, I2=0%),
whereas no significant difference was found between parenteral
PR and parenteral SbV (0.88; 0.56–1.38; P = 0.567; heterogeneity
x2=3.52, P = 0.061, I2=72%). Similar results were observed for
the secondary outcome (data not shown).
Side effects of PR
Only a small number of trials reported extractable data on side
effects. (Table 3) In general, local side effects were more common
with topical treatment and systemic side effects were more
common with parenteral treatment. Local reactions seem to occur
more frequently when topical PR was combined with MBCL
(1.60; 0.98–2.61; P= 0.061; heterogeneity x2=0.15, P = 0.701,
I2=0%), as compared to when topical PR was used alone (1.07;
0.52–2.21; P= 0.850; heterogeneity x2=3.36, P= 0.339,
I2=11%). Systemic side effects were less frequent with topical or
parenteral PR as compared to parenteral SbV [3–5]. Laboratory
data were not available for extraction; however, no significant
difference was reported on blood counts, chemistry, and liver
function tests between any topical PR regimen and placebo [19–
22]. Bone marrow suppression and abnormal liver function tests
were reported more often with parenteral SbV as compared to
parenteral PR [5].
Sensitivity analyses and publication bias
Concealment of treatment allocation was adequate in six trials
[3,16,32,34,35,37] and outcome assessment was blinded in five
trials [3,16,28,32,34]. The intention-to-treat analysis was per-
formed in five trials [4–6,17,35]. Trials that did not meet the study
quality criteria tended to slightly exaggerate the efficacy of PR as
compared to placebo or SbV. (Figure 4) In addition, the pooled
estimates were not significantly changed when an individual trial
was omitted. There was no evidence of publication bias based on
the Begg’s test and Egger’s test (P = 0.621 and P=0.126,
respectively, for placebo-controlled trials; and P= 0.348 and
P= 0.242, respectively, for SbV-controlled trials).
Discussion
In our meta-analysis, we found that topical PR showed
therapeutic activity only when it was combined with MBCL.
Table 3. Side Effects of Paromomycin Compared with
Placebo and Antimony Compounds.
Comparisons Paromomycin (n/N) Control (n/N)
Local reactions*
Topical PR only vs Placebo
El-Safi, 1990 [36] 2/20 0/20
Salah, 1995 [34] 6/52 6/56
Asilian, 1995 [32] 8/126 11/125
Iraji, 2005 [29] 3/40 0/40
RR (95% CI) 1.07 (0.52, 2.21) I2= 11%
Topical PR only vs Intralesional MA
Shazad, 2005 [33] 1/30 3/30
Topical PR only vs Parenteral MA
Armijos, 2004 [3]{ 13/40 0/40
Topical PR/MBCL vs Placebo
El-On, 1992 [37] 3/40 0/16
Arana, 2001 [16] 22/38 14/38
RR (95% CI) 1.60 (0.98, 2.61) I2= 0%
Topical PR/MBCL vs Parenteral MA
Armijos, 2004 [3]{ 7/40 0/40
Myalgia
Topical PR only vs Parenteral MA
Armijos, 2004 [3] 0/40 1/40
Topical PR/MBCL vs Parenteral MA
Armijos, 2004 [3] 0/40 1/40
Parenteral PR vs Parenteral Antimony Compounds{
Hepburn, 1994 [5] 1/17 17/17
Correia, 1996 [4] 2/15 8/16
RR (95% CI) 0.16 (0.05, 0.48) I2= 14%
Generalized Symptoms1
Topical PR only vs Parenteral MA
Armijos, 2004 [3] 2/40 14/40
Topical PR/MBCL vs Parenteral MA
Armijos, 2004 [3] 6/40 14/40
Parenteral PR vs Parenteral Antimony Compounds{
Hepburn, 1994 [5] 0/17 3/17
Correia, 1996 [4] 10/15 12/16
RR (95% CI) 0.64 (0.16, 2.54) I2= 33%
Headache
Topical PR only vs Parenteral MA
Armijos, 2004 [3] 1/40 5/40
Topical PR/MBCL vs Parenteral MA
Armijos, 2004 [3] 2/40 5/40
Parenteral PR vs Parenteral SB
Hepburn, 1994 [5] 0/17 3/17
Arthralgia
Topical PR only vs Parenteral MA
Armijos, 2004 [3] 0/40 1/40
Topical PR/MBCL vs Parenteral MA
Armijos, 2004 [3] 0/40 1/40
Parenteral PR vs Parenteral MA
Correia, 1996 [4] 0/15 5/16
Comparisons Paromomycin (n/N) Control (n/N)
Generalized Eruption
Parenteral PR vs Parenteral SB
Hepburn, 1994 [5] 1/17 1/17
Abbreviations: PR, paromomycin; RR, risk ratio; CI, confidence interval; MBCL,
methylbenzethonium chloride; MA, meglumine antimoniate; SB, sodium
stibogluconate.
*Local reactions include pain, burning sensation, pruritus, erythema, edema,
and inflammation at the site of administration.
{Armijos et al [3] reported the number of subjects who experienced each
category of local side effects, without providing a cumulative number of
subjects. Therefore, the number of those who developed local inflammation
was presented for local reaction.
{Parenteral antimony compounds include parenteral MA and parenteral SB.
1Generalized symptoms include fever, malaise, weakness, and anorexia.
doi:10.1371/journal.pntd.0000381.t003
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Local reactions also tended to increase with MBCL. The efficacy
of topical PR did not differ from that of intralesional SbV in the
old world CL, whereas its efficacy was inferior to parenteral SbV
in the new world CL. No significant difference was found between
parenteral PR and SbV in the new world CL. However, due to
small number and heterogeneous quality of included studies, our
findings should be interpreted with caution.
Randomized controlled trials with placebo control group
Our analysis suggested that topical PR with MBCL showed
therapeutic activity, whereas topical PR with soft paraffin or urea
did not. Our finding is further supported by several lines of
experimental evidence. MBCL, a quaternary ammonium com-
pound, suppresses the growth of L.major in an in vitro model and
increases cutaneous permeability of PR [11,38]. In vivo studies
suggested the synergistic action between PR and MBCL [12,39]. In
a randomized controlled study comparing topical PR with MBCL,
topical PR with urea, and parenteral MA [3], Armijos et al. found a
non-significant higher cure rate in 12% MBCL group than in 10%
urea group (79.3% vs. 70.0%). But the study was underpowered for
the comparison between the two topical regimens. We also found
that local reactions appeared to increase when topical PR was
combined with MBCL. It is not clear whether a lower MBCL
concentration (i.e., 5% vs. 12%) can reduce local reactions without
compromising efficacy. El-On et al. compared 5% and 12%MBCL
as an adjunct to topical PR, and found cure rates of 66.6% and
76.6%, respectively [37]. Severe local reactions were observed only
in patients treated with 12%MBCL. However, other characteristics
of topical formulas, including the composition of vehicle [40,41] and
application methods, such as occlusion [42], also play key roles in
determining the efficacy.
Although the type of topical PR was responsible for the
heterogeneity among placebo-controlled trials, other important
clinical factors, such as differences in parasite species and their
clinical manifestation (i.e. self-cure rate and types of lesions), length
of treatment, and duration of the lesions should be considered for
several reasons. The tendency for spontaneous cure or progression
to a more severe form of CL varies among the species. Even in the
old world CL, spontaneous cure rate at 3 months is 60–70% for
L.major, but,1% for L.tropica [8]. Moreover, L.braziliensis infection is
associated with a more severe and prolonged course, a higher risk of
progression to mucocutaneous form [8], and a lower self-healing
rate [43]. Among placebo-controlled trials included in our meta-
analysis, the clinical cure rate varied by species: up to 68% for
L.major, 3% for L.chagasi, and 34% for L.braziliensis. Limited in vitro
and in vivo observations also suggested that the new world CL was
more refractory to PR than the old world CL [15,44]. Although an
in vitro [39] and several human studies [3,16,43,45] of topical PR
with MBCL demonstrated its efficacy against the new world CL,
most clinicians do not use local treatments for L.braziliensis complex
infection. Another important characteristic to be considered is the
type of lesions. Depending on the stages of infection and species,
lesions can vary from small erythema to nodular or ulcerative lesions
[8]. Ulcerated lesions are typical of L.major and the new world
species, whereas nodular lesions are typical of L.aethiopica and
L.donovani and hyperkeratotic lesions of L.tropica. Topical agents may
Figure 4. Influence of Study Quality Criteria on Pooled Estimates*. * Pooled RRs and 95% CIs of clinical cure were calculated by study quality
components, using an inverse-variance weighted random-effects model. { Adjusted for paromomycin regimen among trials with placebo control
group and for antimony regimen among trials with pentavalent antimony compound control group.
doi:10.1371/journal.pntd.0000381.g004
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have better absorption in ulcerative lesions than in nodular lesions.
Such differences in clinical features were not well-reflected in our
analysis due to the limited data and a small number of trials.
Lack of significant association between the length of treatment
and its efficacy in meta-regression analysis does not necessarily
exclude the benefit of a longer treatment course. In fact, none of
the included trials involved a direct comparison. Asilian et al.
randomly assigned patients with CL caused by L.major to either
two-week or four-week PR treatment, and found a significantly
better cure rate and reduced need for SbV rescue treatment in the
four-week group [22]. Even a small improvement in cure rate can
lead to considerable benefit to patients by avoiding serious
systemic side effects by SbV treatment.
In a self-healing disease like CL, the duration of lesions may
have a crucial role on cure rate. Insufficient number and
inadequate reporting [6,17,34–36] of included trials did not allow
enough power to detect the trend, but it is possible that the efficacy
of PR may diminish, as the lesions get older.
Randomized controlled trials with SbV control group
An inadequate number of trials did not allow us to examine the
efficacy of various PR and SbV regimens for each parasite species.
No trials compared the combination of topical PR and MBCL
with intralesional or parenteral SbV in the old world CL; or
topical PR and intralesional SbV in the new world CL. In general,
the old world CL is treated with intralesional SbV, whereas the
new world CL is treated with parenteral SbV due to high risk of
mucocutaneous involvement [8]. Our study suggests that topical
and parenteral PR have lower side effects as compared to
intralesional and parenteral SbV.
Limitations
A major limitation to our study is the small number of included
trials. There were several comparisons that were based on only
two to three trials. This increases the uncertainty of pooled
estimates. Certain species, such as L.tropica, have not been
examined in the included trials. These limit generalizability of
our findings. In addition, overall poor quality in conducting and
reporting trials was noted. El-On et al. [37] used a cross-over
design which is less desirable in assessing the efficacy of a
treatment in a self-limited disease, as criticized in a recent review
[46]. Inadequate reporting of demographic characteristics of
participants [3,5,6,16,35,36], parasite species [3,17,29], duration
of lesions [6,17,34–36], and quantitative data on side effects
[6,17,18,24,27,28] were very common. Standardization of study
protocols has been suggested to facilitate between-study compar-
isons [47]. Furthermore, in our sensitivity analysis, trials that did
not meet the study quality criteria tended to slightly exaggerate the
efficacy of PR compared with control group. For unbiased and
reliable evaluation, investigators should address appropriate
quality criteria in design and conduct of trials and strictly follow
the reporting standards such as CONSORT [48,49]. Finally,
publication bias cannot be excluded reliably in our meta-analysis,
because of low sensitivity of the Begg’s test and Egger’s test in
meta-analyses of fewer than 20 trials [50]. However, it has been
reported that publication bias did not change the conclusions in
most cases [51].
Implications
The main findings of our meta-analysis can be summarized as the
following: 1) topical PR appears to demonstrate therapeutic activity
against the old world and new world CL, with a tendency of
increased local reactions, when it was combined with MBCL; 2) in
the old world CL, the efficacy of topical PR is not different from that
of intralesional SbV; and 3) in the new world CL, the efficacy of
topical PR is inferior to that of parenteral SbV, whereas the efficacy
of parenteral PR is not different from that of parenteral SbV.
Although similar findings have been described in the past
[8,16,22,52], a valuable contribution of our meta-analysis is to
provide their quantitative dimension. For clinicians, this meta-
analysis confirms that the existing evidence does not support topical
PR as an acceptable treatment of the new world CL. However,
topical PR with MBCL could be a therapeutic alternative for
selected cases of old world CL with lower risk of mucocutaneous
involvement, due to its lack of serious systemic side effects.
An acceptable alternative should demonstrate efficacy as well as
local tolerability to ensure compliance. Sustained availability is
also an issue. To this end, the efforts are currently made to develop
formulations that has equivalent efficacy to that of first-generation
formulations and local side effect profile similar to that of second-
generation formulations [52]. For instance, a few randomized
controlled trials evaluating a new topical PR-based formulation,
WR 279396, compared to placebo or pure topical PR in CL
caused by L.major are under way. This new formation was found to
have therapeutic activity as well as cosmetic effects in an animal
model [41]. Future research on topical PR in treatment of the old
world CL merits addressing the following issues: examining the
efficacy of various topical PR regimens in other species, such as
L.tropica; comparison between topical PR with MBCL and topical
PR only; evaluation of topical PR with different MBCL
concentration for their efficacy and tolerability; and development
of new formulations that has similar or superior efficacy and better
tolerability than topical PR and MBCL.
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